takeover prospects, page-10

Dont buy into this kind of debate- just leads to alot of negative back and forth with no real content that puts people off.

Revenue forecasts have been provided by the company for Germany. They expect Bronchitol to be 50% of the adult market for pulmoz. but have not given a timeframe.

From the conference call in January- In Germany they anticipated another 150 patients to take their first supervised dose of B this Qtr. I believe that only some 6% of patients in Germany have started on B. Supervision and observation of patients in the first 3 months of trying B is essential to ensure safety so we cant expect a rush of sales

Bronchitol is only now just on UK hospital formularies so sales can be made this qtr- 90 days from NICE approval was up at the end of January.

There will be a steady ramp up in sales in Europe- Austria, Denmark also selling B. France reimbursement is the next- hopefully they were not put off reimbursement approval from FDA committee opinion.

Australian- PXS is seeking to get easier access to B. for Australian patients- PBS is meeting this month to dicuss.

If there is a delayed launch of Bronchitol in the US that may actually be a blessing in disguise as may save us in marketing costs untill sales of B. in Europe and Aust are at a sustainable level. PXS should have received the US$20 million by now so the cash balanace should be some $80 million- enough for at least a year!